| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/10000 | Human,Mouse,Rat |
| Aliases | HsT16992; cPLA2-beta |
| WB Predicted band size | 88 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human PLA2G4B |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于PLA2G4B抗体的模拟参考文献示例(注：部分文献信息为假设性概括，建议通过学术数据库核实具体内容)：
1. **标题**: "Characterization of a Novel Polyclonal Antibody Against PLA2G4B and Its Application in Lipid Metabolism Studies"
**作者**: Kim H, et al.
**摘要**: 研究报道了一种针对PLA2G4B的多克隆抗体的开发与验证，通过免疫印迹和免疫组化证实其在肝组织中的特异性表达，并发现PLA2G4B与脂质代谢异常相关。
2. **标题**: "PLA2G4B Expression in Atherosclerosis: Insights from Antibody-Based Immunodetection"
**作者**: Müller R, et al.
**摘要**: 利用抗PLA2G4B抗体分析动脉粥样硬化斑块中的表达模式，发现其与炎症细胞浸润及氧化应激标志物共定位，提示其在血管疾病中的潜在作用。
3. **标题**: "A Monoclonal Antibody Targeting PLA2G4B Suppresses Tumor Growth in Mouse Xenograft Models"
**作者**: Chen X, et al.
**摘要**: 开发了一种单克隆抗体，通过阻断PLA2G4B的酶活性抑制肿瘤细胞增殖，在乳腺癌小鼠模型中显著降低肿瘤体积，表明其治疗潜力。
4. **标题**: "PLA2G4B Gene Knockout Validation Using CRISPR and Antibody-Based Phenotypic Screening"
**作者**: Sato Y, et al.
**摘要**: 结合CRISPR基因编辑技术和抗PLA2G4B抗体，验证了基因敲除小鼠模型中蛋白表达的缺失，并发现其与肠道屏障功能缺陷相关。
**提示**：以上为模拟示例，实际文献需通过PubMed、Google Scholar等平台以关键词“PLA2G4B antibody”或“phospholipase A2 IVB antibody”检索获取最新研究。
Phospholipase A2 Group IVB (PLA2G4B) is a member of the phospholipase A2 enzyme family, which hydrolyzes phospholipids to release free fatty acids, including arachidonic acid, a precursor for inflammatory mediators. PLA2G4B, also known as cytosolic phospholipase A2 beta (cPLA2β), shares structural homology with the well-studied PLA2G4A (cPLA2α) but exhibits distinct tissue expression patterns and regulatory mechanisms. It is implicated in membrane remodeling, lipid signaling, and inflammatory responses, though its specific biological roles remain less characterized compared to other PLA2 isoforms.
Antibodies targeting PLA2G4B are critical tools for investigating its expression, localization, and function in physiological and pathological contexts. These antibodies are commonly validated for applications such as Western blotting, immunohistochemistry, and immunofluorescence. Research suggests PLA2G4B may contribute to diseases involving lipid dysregulation, such as cancer, metabolic disorders, or neurodegenerative conditions, though conclusive evidence is limited.
Commercial PLA2G4B antibodies are typically raised against unique peptide sequences or recombinant protein fragments to ensure specificity. Researchers must verify cross-reactivity with homologous isoforms, particularly PLA2G4A, to avoid misinterpretation. Recent studies highlight its potential as a biomarker or therapeutic target, driving demand for reliable antibodies to advance mechanistic insights. However, the functional ambiguity of PLA2G4B underscores the need for further exploration using antibody-based methodologies.
×
